Cambridge Investment Research Advisors
ESPR

Cambridge Investment Research Advisors’s Esperion Therapeutics ESPR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,770
Closed -$363K – 2740
2020
Q3 		$363K Buy
9,770
+5,385
+123% +$213K ﹤0.01% 1806
2020
Q2 		$225K Buy
+4,385
New +$183K ﹤0.01% 2101
2020
Q1 		– Sell
-3,366
Closed -$201K – 2323
2019
Q4 		$201K Buy
+3,366
New +$151K ﹤0.01% 2208

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Cambridge Investment Research Advisors's ESPR Position: Q4 2020 in Review

Cambridge Investment Research Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 9,770 shares — an estimated $363K sold.

Cambridge Investment Research Advisors first reported a position in ESPR in Q4 2019 and held it in 3 quarters. The position peaked at $363K in Q3 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Cambridge Investment Research Advisors reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 9,770 Esperion Therapeutics shares in Q4 2020, an estimated $363K.
  • Cambridge Investment Research Advisors first reported a position in Esperion Therapeutics in Q4 2019 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Esperion Therapeutics position peaked at $363K in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2020, filed 4 Feb 2021.